Mallinckrodt Pharmaceuticals News

2,44 $ -8,27% -0,22 $
In : 2,1883 € | 19:09:15 Uhr NYSE | Mehr Kurse »
WKN: A1W0TN
ISIN: IE00BBGT3753
US-Symbol: MNK
Typ: Aktie

Mallinckrodt Pharmaceuticals News

  
16:15 Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) at The Liver Meeting® 2019 PR Newswire
09.10.19 Mallinckrodt to Report Earnings Results for Third Quarter 2019 PR Newswire
01.10.19 Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection) PR Newswire
30.09.19 Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit PR Newswire
23.09.19 Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-​thickness Thermal Burns PR Newswire
20.09.19 Mallinckrodt to Present at Cantor Global Healthcare Conference PR Newswire
19.09.19 FINAL DEADLINE ALERT - Mallinckrodt plc (MNK) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: September 24, 2019 PR Newswire
18.09.19 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Mallinckrodt Plc (NYSE: MNK) and Encourages Mallinckrodt Investors to Contact the Firm PR Newswire
13.09.19 Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-​Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse PR Newswire
10.09.19 Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million PR Newswire
06.09.19 Mallinckrodt Announces Settlement in Principle to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit PR Newswire
06.09.19 S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600 PR Newswire
03.09.19 Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities PR Newswire
24.08.19 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline - MNK PR Newswire
21.08.19 Mallinckrodt to Present at Morgan Stanley 17th Annual Global Healthcare Conference PR Newswire
15.08.19 Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) PR Newswire
13.08.19 Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns PR Newswire
12.08.19 First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE) PR Newswire
06.08.19 Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off PR Newswire
02.08.19 Mallinckrodt to Present at Wells Fargo Securities 2019 Healthcare Conference PR Newswire
31.07.19 ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Mallinckrodt plc; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MNK PR Newswire
29.07.19 LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm PR Newswire
18.07.19 Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-​Mediated Diseases PR Newswire
18.07.19 Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-​Mediated Diseases PR Newswire
16.07.19 Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) PR Newswire
01.07.19 Mallinckrodt to Report Earnings Results for Second Quarter 2019 PR Newswire
25.06.19 Thinking about trading options or stock in Alibaba, Coupa Software, Electronic Arts, Mallinckrodt, or Pfizer? PR Newswire
24.06.19 Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS) PR Newswire
13.06.19 All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR) PR Newswire
11.06.19 Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference PR Newswire
05.06.19 Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities PR Newswire
31.05.19 RM LAW Announces Investigation of Mallinckrodt plc PR Newswire
31.05.19 Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference PR Newswire
29.05.19 Mallinckrodt Announces Positive Open-​Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR) PR Newswire
28.05.19 Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders PR Newswire
22.05.19 Wolf Popper LLP Announces Investigation on Behalf of Investors in Mallinckrodt plc PR Newswire
21.05.19 Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of Directors PR Newswire
21.05.19 Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel PR Newswire
14.05.19 Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial PR Newswire
13.05.19 Lifshitz & Miller LLP Announces Investigation of Glencore plc, Kingstone Companies, Inc., Mallinckrodt PLC, Metro Bank PLC, Momo Inc., Nabriva Therapeutics PLC, National General Holdings Corp, and Zillow Group, Inc. PR Newswire
07.05.19 Mallinckrodt: KGV 2 dank Megazahlen LYNX Analysen
07.05.19 Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation PR Newswire
07.05.19 Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis PR Newswire
06.05.19 Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates PR Newswire
02.05.19 MALLINCKRODT (MNK) ALERT: Johnson Fistel, LLP Commences Investigation of Mallinckrodt PLC; Encourages all Investors to Contact the Firm for Information PR Newswire
02.05.19 Mallinckrodt to Present Open-​Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019) PR Newswire
24.04.19 Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. PR Newswire
23.04.19 Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-​to-Manage Population PR Newswire
18.04.19 Mallinckrodt Reports Top-Line Results from Proof-​of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants PR Newswire
15.04.19 Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL) PR Newswire

Newssuche

  

Videos

  
17:23 Uhr +2,15%
Deutsche Bank X-Markets: Exklusiv-​Interview mit Christian-​Hendrik Knappe – Video